TLR7 and neoplasm: Single IT administration of soluble resiquimod was compared to TransCon TLR7/8 Agonist containing an equivalent dose of soluble resiquimod in CT26 tumor-bearing mice and tumor growth inhibition and systemic cytokine induction were assessed.